AJOVY™ is the first and only anti-CGRP
treatment with both quarterly and monthly dosing for the preventive
treatment of migraine in adults
- AJOVY™ is supported by the AJOVY™ Teva Support Solutions®
(AJOVY TSS) Patient Support Program, whose services include
reimbursement navigation, bridging/copay coverage, and injection
training.
- AJOVY™ has been studied in patients with chronic or episodic
migraine and was shown to significantly reduce patients' mean
monthly migraine days—with some patients achieving a 50% reduction
or more.1–3
MONTRÉAL, Aug. 19, 2020 /CNW/
- Teva Canada, a subsidiary of Teva Pharmaceutical Industries
Ltd., today announced product availability of AJOVY™ (fremanezumab)
225 mg solution for subcutaneous injection for the preventive
treatment of migraine in adults who have at least four migraine
days per month. AJOVY™ is the first and only anti-CGRP drug
approved in Canada, the European
Union, and the United States that
offers quarterly or monthly dosing regimens for the preventive
treatment of migraine. The quarterly dose of 675 mg is given
as three 225 mg subcutaneous injections once every three months;
the monthly dose of 225 mg is given as one subcutaneous injection
once each month. AJOVY™ is currently available in a latex-free
prefilled syringe. 1–3
"Canadian patients and prescribers have been waiting for a
product like AJOVY™ that offers flexible dosing options
convenient for their busy lifestyles," says Christine Poulin, General Manager of
Teva Canada. "With the product now
in distribution across Canada, Teva
Canada is also introducing a comprehensive patient support
program to educate patients and provide financial support to
meet the various needs of Canadians who suffer with the
condition."
Migraine is a disabling chronic neurological disease that causes
head pain so severe that sufferers often cannot function during an
attack. Migraine reduces quality of life and disrupts migraineurs'
ability to perform daily activities.4,5 It is among the
top 10 causes of disability worldwide and the seventh cause of
years of life lost to disability.6–8 In Canada,
migraine is most common in women and most common between the ages
of 30 and 49.9
Dr. Elizabeth Leroux, president
of the Canadian Headache Society and founder of the websites
Migraine Quebec and Migraine Canada, says the availability of
AJOVY™ is good news for all migraine patients and treaters.
"The unique dosing options that AJOVY™ offers will provide
added flexibility and stability for many patients to manage their
symptoms with less disruption to their lives and routines. This is
a welcome next step in migraine management."
AJOVY™ was evaluated in two pivotal Phase III clinical
trials that enrolled patients with disabling migraine and studied
fremanezumab as a prophylactic treatment. In these trials, efficacy
assessments included the change from baseline in the number of
average monthly migraine or headache days and the proportion of
patients achieving at least a 50% reduction in affected days. The
safety profile was also assessed in these
trials.1–3
About the AJOVY™ Teva Support Solutions® (AJOVY
TSS) Patient Support Program
AJOVY™ patients and prescribers are supported by the
AJOVY™ Teva Support Solutions® Patient Support Program, which
was developed in collaboration with Canadian migraine experts and
offers services such as injection training, insurance/coverage
investigation, and paperwork assistance.
About AJOVY™
AJOVY™ (fremanezumab) is indicated for the preventive
treatment of migraine in adults who have at least four migraine
days per month. AJOVY™ is available as a 225 mg/1.5 mL
single-dose injection in a prefilled syringe with two dosing
options: 225 mg monthly, administered as one subcutaneous
injection; or 675 mg every three months (quarterly), administered
as three subcutaneous injections. AJOVY™ is intended for
patient self-administration after the patient or their caretaker
has been trained to administer the product.
Helping improve the lives of Canadians
At Teva, we are committed to providing innovative and quality
medicines to the nearly 200 million people we serve around the
world every day. From our role as a global leader in generic and
brand name medicines to the innovative solutions we create for our
healthcare partners, we offer a unique perspective on health—here
in Canada and around the
world.
About Teva Canada
Teva Canada, headquartered in
Toronto, has provided affordable
healthcare solutions to Canadians for over 50 years, building their
trust one prescription at a time with now more than
217,00010 prescriptions filled each day with our
products. Originally Novopharm Limited, Teva Canada specializes in the development,
production, and marketing of high-quality generic prescription
pharmaceuticals and, through our branded division, focuses on a
diverse line of innovative products in a variety of therapeutic
areas. Teva Canada employs more than
900 professionals, had sales of nearly $1.3
billion10 in 2019, and markets more than 385
products in 1,000 SKUs10 in Canada. We are a proud subsidiary of Teva
Pharmaceutical Industries Ltd. Learn more at
www.tevacanada.com.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people's lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
___________________________________________
|
|
CGRP: calcitonin
gene-related peptide; SKU: Stock Keeping Unit
|
1.
|
AJOVY™ Product
Monograph. Teva Canada Limited, Montréal, Quebec. April 9,
2020.
|
2.
|
Dodick DW et al.
Effect of fremanezumab compared with placebo for prevention of
episodic migraine. JAMA. 2018;319(19):1999–2008. doi:
10.1001/jama.2018.4853.
|
3.
|
Silberstein SD et al.
Fremanezumab for the preventive treatment of chronic migraine. N
Engl J Med. 2017;377(22):2113–2122. doi:
10.1056/NEJMoa1709038.
|
4.
|
Buse DC, Rupnow MF,
Lipton RB. Assessing and managing all aspects of migraine: migraine
attacks, migraine-related functional impairment, common
comorbidities, and quality of life. Mayo Clin Proc.
2009;84:422–435. doi: 10.1016/S0025-6196(11)60561-2.
|
5.
|
Lipton RB, Liberman
JN, Kolodner KB, et al. Migraine headache disability and
health-related quality-of-life: a population-based case-control
study from England. Cephalalgia. 2003;23:441–450. doi:
10.1046/j.1468-2982.2003.00546.x.
|
6.
|
Steiner TJ, Stovner
LJ, Birbeck GL. Migraine: the seventh disabler. J Headache
Pain. 2013;14:1. doi: 10.1186/1129-2377-14-1.
|
7.
|
Global Burden of
Disease Study Collaborators. Global, regional, and national
incidence, prevalence, and years lived with disability for 301
acute and chronic diseases and injuries in 188 countries,
1990–2013: a systematic analysis for the Global Burden of Disease
Study 2013. Lancet. 2015;386:743–800. doi:
10.1016/S0140-6736(15)60692-4.
|
8.
|
Institute for Health
Metrics and Evaluation. Global burden of disease visualization
tools. Available from: http://vizhub.healthdata.org/gbd-compare/.
Accessed January 2016.
|
9.
|
Ramage-Morin PL,
Gilmour H. Prevalence of migraine in the Canadian household
population. Health Rep. 2014;25(6):10–16.
|
10.
|
Source: IQVIA CDH
& Compuscript MAT. April 2020.
|
SOURCE Teva Canada